neotract recoveri
durabl evid result variou segment
portfolio insul acut procedur
disrupt neotract impact like sever asc/offic
skew aid recoveri path remain overweight
durabl expect report revenu
organ pre-covid estim compani estim
global headwind steril headwind
adjust factor see underli organ growth closer
bp momentum acceler vascular intervent anesthesia
segment rel durabl normal oem
normal normal much stronger expect
although latter saw tailwind elev demand respiratori
product like continu sever impact seen
surgic neotract came normal exhibit
normal exhibit segment ep grew y/i includ
fx impact steril impact impact
therefor underli ep growth closer y/i driven
durabl revenu discuss higher margin vs
mse due favor mix cost initi
neotract trough seen segment like lead recoveri urolift growth
track februari although declin march impli back
trend worsen margin howev like bottom modestli
lower neotract assumpt normal
visibl patient referr channel skew older average age
per lift studi said discuss neotract
forefront us procedur recoveri given procedur perform
asc/offic set see view reinforc boston
yesterday regard rezum see see neotract recoveri
augment procedur profit see compar favor
rezum updat includ urolift submiss delay
june/juli launch japan roll-out track
although shift vs prior nation dtc campaign
delay remain bullish dtc prospect given region success seen
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
last year see prudent delay roll-out like
durabl surpris withdrew guidanc
forward look comment limit howev qualit
commentari provid framework durabl lie within
busi re-calibr model base result
convers top-line see organ growth declin like
neotract see acut impact near-term beyond
forecast flat organ growth follow remain
rel unchang detail review segment see addit
manag headwind consist major coverag
taken initi control near-term spend period acut
busi disrupt variou action highlight includ adjust
management/execut compens elimin non-essenti
spend notabl compani furlough laid-off employe
prepar signific recoveri expect re-calibr margin
 assumpt forecast mid-teen oper margin
ramp signific margin pressur
natur occur may hinder unfavor mix
neotract surgic sale expect pressur howev
cost save previous announc program order mitig near-term
pressur note increment cost save drive bp
margin ep
durabl phase recoveri asset remain overweight part
phase recoveri model view phase recoveri stori given
non-emerg procedur exposur neotract surgic intervent would
modestli off-set durabl key portfolio region vascular
respiratori appar result like slightli past
trough see portfolio well posit lead phase
recoveri highlight neotract net leverag see
leverage/liquid concern also drew revolv per
recent manag reiter remain core principl
compani strategi although recogn activ like limit near-term
despit attract valuat rais price target base
ep estim repres premium larg cap peer
see warrant given structur higher organ growth ep profil
price target base ep four-turn premium larg cap
devic peer see justi given outsiz organ growth margin prole
organ growth prole
maintain durabl driven
neotract vsi manta core busi
lrp margin target appear steep
variou factor includ sale mix cost
neotract growth margin potenti
greater guidanc consensu
view descript risk reward theme
impact mute given
durabl vascular offset
durabl dtc program acceler
intervent etc drive pt gross
margin expans annual
restructur program gener busi
leverag lead pt margin
expans
impact less sever versu peer
impact near-term may recov
faster similar elect procedur given
favor mix cost save program
busi leverag allow mid-teen
neotract procedur signicantli
impact dtc program
delay year competit pressur
rezum intensifi core
target like achiev given
organ growth prole acceler
neotract contribut pt growth
manta revenu translat
addit pt growth
dtd convers restructur program
drive high teen ep growth
china india
view explan region hierarchi
research highest favor quintil
materi margin expans driven
favor mix cost program
manta add point growth
materi delay reach
lrp margin target core busi
rezum success take market share
ofc set
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
vascular normal growth acceler march driven heighten
demand picc ez-io product expect demand product
categori remain elev near-term forecast modest absolut growth
deceler q/q given tougher comp
intervent normal although segment organ growth flat
revenu durabl anticip driven iabp manta
oncontrol off-set declin complex drainag cathet
manag note slowdown non-emerg procedur ie tavr seen
march/april like lead segment declin model organ
growth may prove conserv
anesthesia normal neglig impact covid
growth declin consist prior trend driven lower sale laryng
mask region product expect acut impact
epidur pain manag product forecast declin worsen
although note greater demand airway manag product may partial
surgic normal materi impact seen covid
steril model declin acceler organ given elect
procedur exposur note rel unchang prior estim
neotract normal discuss expect neotract see
signific impact specif april howev given access skew
office/asc set see segment lead recoveri thereaft
model declin follow rebound growth
oem normal growth stronger expect covid
impact observ although unclear stock factor roughli half
oem busi cathet growth like acceler
howev half expos surgic sutur like declin
similar magnitud see modest step-down like model msd
normal overli surpris given elev
demand respiratori product ie filter humidifi led growth
respiratori portfolio like remain elev near-term
urolog cathet portfolio grew mid-teen march also see stabl near-
term forecast acceler segment mid-teen
million except ep
million
sale
sale
sale
sale
sale
sale
sale
sale
good sold
net incom sharehold
net incom sharehold
prepaid expens current asset
asset held sale
properti equip net
invest affili
payrol benefit-rel liabil
pension post-retir benefit
non-current liabil uncertain tax posit
addit paid capit
incom discontinu oper
amort expens intang asset
amort expens defer financ
loss extinguish debt
net loss sale busi asset
chang oper asset liabil
net provid use oper activ
expenditur properti plant equip
proce sale busi asset
payment busi intang acquir net
invest affili
net use invest activ
proce long-term borrow
repay long-term debt
increas decreas note payabl current borrow
proce stock compens
proce non-controlling interest
debt equiti issuanc amend
purchas call option
proce sale warrant
discontinu oper
net cash use provid discontinu oper
effect exchang rate ce
net chang
equival bop
equival eop
